I think there's a little bit of negative sentiment in the market. Back-to-school sales at retailers were not especially great, and that put a little damper on things. People start focusing on valuations, which is an old story. But valuations are still, you know, pretty high,
But they are a big deal when you start to think who they are selling to -- biotech companies.